{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:14:22Z","timestamp":1790874862539,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00106"],"award-info":[{"award-number":["PI20\/00106"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00137"],"award-info":[{"award-number":["PI20\/00137"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005774","name":"Universitat de Barcelona","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.bcp.2023.116010","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T11:01:33Z","timestamp":1703588493000},"page":"116010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Divergent effects of the antiretroviral drugs, dolutegravir, tenofovir alafenamide, and tenofovir disoproxil fumarate, on human adipocyte function"],"prefix":"10.1016","volume":"220","author":[{"given":"T.","family":"Quesada-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Cereijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Blasco-Roset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mestres-Arenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Villarroya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7968-4190","authenticated-orcid":false,"given":"M.","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2023.116010_b0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.bcp.2023.116010_b0010","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/COH.0000000000000781","article-title":"HIV and obesity: updates in management strategies","volume":"18","author":"Parra-Rodriguez","year":"2023","journal-title":"Curr Opin HIV AIDS"},{"issue":"1","key":"10.1016\/j.bcp.2023.116010_b0015","doi-asserted-by":"crossref","first-page":"54","DOI":"10.24875\/AIDSRev.22000026","article-title":"Antiretroviral therapy and weight gain in antiretroviral treatment-experienced HIV patients: A review","volume":"25","author":"Dupont","year":"2023","journal-title":"AIDS Rev"},{"key":"10.1016\/j.bcp.2023.116010_b0020","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.metabol.2018.09.005","article-title":"The epidemiology of obesity","volume":"92","author":"Chooi","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.bcp.2023.116010_b0025","doi-asserted-by":"crossref","unstructured":"A. Menard, et al., Dolutegravir and weight gain: an unexpected bothering side effect?, AIDS 31 (10) (Jun. 2017) 1499\u20131500, doi:10.1097\/QAD.0000000000001495.","DOI":"10.1097\/QAD.0000000000001495"},{"issue":"1","key":"10.1016\/j.bcp.2023.116010_b0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/QCO.0000000000000616","article-title":"Weight gain and integrase inhibitors","volume":"33","author":"Eckard","year":"2020","journal-title":"Curr Opin Infect Dis"},{"issue":"8","key":"10.1016\/j.bcp.2023.116010_b0035","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1093\/jac\/dky145","article-title":"Obesity following ART initiation is common and influenced by both traditional and HIV-\/ART-specific risk factors","volume":"73","author":"Bakal","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bcp.2023.116010_b0040","doi-asserted-by":"crossref","unstructured":"J. R. Koethe et al., \u201cHIV and antiretroviral therapy-related fat alterations.,\u201d Nat Rev Dis Primers, vol. 6, no. 1, p. 48, Jun. 2020, doi: 10.1038\/s41572-020-0181-1.","DOI":"10.1038\/s41572-020-0181-1"},{"issue":"7","key":"10.1016\/j.bcp.2023.116010_b0045","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/cid\/ciz407","article-title":"Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy","volume":"70","author":"Bourgi","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bcp.2023.116010_b0050","doi-asserted-by":"crossref","unstructured":"P. E. Sax et al., \u201cWeight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials.,\u201d Clin Infect Dis vol. 71, no. 6, pp. 1379\u20131389, Sep. 2020, doi: 10.1093\/cid\/ciz999.","DOI":"10.1093\/cid\/ciz999"},{"issue":"9","key":"10.1016\/j.bcp.2023.116010_b0055","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV","volume":"381","author":"Venter","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bcp.2023.116010_b0060","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S2352-3018(20)30115-6","article-title":"Weighing considerations with newer antiretrovirals","volume":"7","author":"Venter","year":"2020","journal-title":"Lancet HIV"},{"issue":"8","key":"10.1016\/j.bcp.2023.116010_b0065","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/hiv.13488","article-title":"Weight gain following the single substitution of tenofovir disoproxil fumarate by tenofovir alafenamide in HIV-infected people from the French Dat\u2019AIDS cohort: A propensity score-matched analysis","volume":"24","author":"Hocqueloux","year":"2023","journal-title":"HIV Med"},{"issue":"9","key":"10.1016\/j.bcp.2023.116010_b0070","doi-asserted-by":"crossref","first-page":"e471","DOI":"10.1093\/cid\/ciaa177","article-title":"Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy","volume":"71","author":"Lake","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bcp.2023.116010_b0075","doi-asserted-by":"crossref","unstructured":"P. W. Mallon et al., \u201cWeight gain before and after switch from TDF to TAF in a U.S. cohort study.,\u201d J Int AIDS Soc, vol. 24, no. 4, p. e25702, Apr. 2021, doi: 10.1002\/jia2.25702.","DOI":"10.1002\/jia2.25702"},{"issue":"3","key":"10.1016\/j.bcp.2023.116010_b0080","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/QAI.0000000000002447","article-title":"Metabolic Changes Associated With the Use of Integrase Strand Transfer Inhibitors Among Virally Controlled Women","volume":"85","author":"Summers","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.bcp.2023.116010_b0085","doi-asserted-by":"crossref","unstructured":"N. S. Nolan, S. Adamson, D. Reeds, and J. A. O\u2019Halloran, \u201cBictegravir-Based Antiretroviral Therapy-Associated Accelerated Hyperglycemia and Diabetes Mellitus.,\u201d Open Forum Infect Dis, vol. 8, no. 5, p. ofab077, May 2021, doi: 10.1093\/ofid\/ofab077.","DOI":"10.1093\/ofid\/ofab077"},{"issue":"12","key":"10.1016\/j.bcp.2023.116010_b0090","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1093\/cid\/ciac355","article-title":"Integrase Strand Transfer Inhibitors Are Associated With Incident Diabetes Mellitus in People With Human Immunodeficiency Virus","volume":"75","author":"O\u2019Halloran","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.bcp.2023.116010_b0095","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41366-020-0551-5","article-title":"Potential role of the melanocortin signaling system interference in the excess weight gain associated to some antiretroviral drugs in people living with HIV","volume":"44","author":"Domingo","year":"2020","journal-title":"Int J Obes (lond)"},{"issue":"10","key":"10.1016\/j.bcp.2023.116010_b0100","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1055\/s-2005-870526","article-title":"The effect of the HIV protease inhibitor ritonavir on proliferation, differentiation, lipogenesis, gene expression and apoptosis of human preadipocytes and adipocytes","volume":"37","author":"Grigem","year":"2005","journal-title":"Horm Metab Res"},{"issue":"3","key":"10.1016\/j.bcp.2023.116010_b0105","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3851\/IMP1533","article-title":"HIV protease inhibitors activate the adipocyte renin angiotensin system","volume":"15","author":"Boccara","year":"2010","journal-title":"Antivir Ther"},{"issue":"3","key":"10.1016\/j.bcp.2023.116010_b0110","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3851\/IMP1988","article-title":"Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes","volume":"17","author":"Capel","year":"2012","journal-title":"Antivir Ther"},{"issue":"6","key":"10.1016\/j.bcp.2023.116010_b0115","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1128\/AAC.00104-12","article-title":"Effects of rilpivirine on human adipocyte differentiation, gene expression, and release of adipokines and cytokines","volume":"56","author":"D\u00edaz-Delf\u00edn","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2023.116010_b0120","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.antiviral.2016.05.013","article-title":"Impact of elvitegravir on human adipocytes: Alterations in differentiation, gene expression and release of adipokines and cytokines","volume":"132","author":"Moure","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bcp.2023.116010_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120948","article-title":"Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytes","volume":"308","author":"Domingo","year":"2022","journal-title":"Life Sci"},{"issue":"10","key":"10.1016\/j.bcp.2023.116010_b0130","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1093\/cid\/ciaa259","article-title":"The Integrase Inhibitors Dolutegravir and Raltegravir Exert Proadipogenic and Profibrotic Effects and Induce Insulin Resistance in Human\/Simian Adipose Tissue and Human Adipocytes","volume":"71","author":"Gorwood","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.bcp.2023.116010_b0135","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1093\/jac\/dkab158","article-title":"Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV","volume":"76","author":"Gonz\u00e1lez-Cord\u00f3n","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bcp.2023.116010_b0140","doi-asserted-by":"crossref","unstructured":"K. Ngono Ayissi et al., \u201cInhibition of Adipose Tissue Beiging by HIV Integrase Inhibitors, Dolutegravir and Bictegravir, Is Associated with Adipocyte Hypertrophy, Hypoxia, Elevated Fibrosis, and Insulin Resistance in Simian Adipose Tissue and Human Adipocytes.,\u201d Cells, vol. 11, no. 11, Jun. 2022, doi: 10.3390\/cells11111841.","DOI":"10.3390\/cells11111841"},{"issue":"9","key":"10.1016\/j.bcp.2023.116010_b0145","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1093\/infdis\/jiac175","article-title":"Dolutegravir Suppresses Thermogenesis via Disrupting Uncoupling Protein 1 Expression and Mitochondrial Function in Brown\/Beige Adipocytes in Preclinical Models","volume":"226","author":"Jung","year":"2022","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.bcp.2023.116010_b0150","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/QAD.0000000000003455","article-title":"Adipocyte differentiation of 3T3-L1 cells under tenofovir alafenamide, tenofovir disoproxil fumarate, and integrase strand transfer inhibitors selective challenge: an in-vitro model","volume":"37","author":"Perna","year":"2023","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.bcp.2023.116010_b0155","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/sj.ijo.0801520","article-title":"Characterization of a human preadipocyte cell strain with high capacity for adipose differentiation","volume":"25","author":"Wabitsch","year":"2001","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.bcp.2023.116010_b0160","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.antiviral.2018.04.002","article-title":"Adipocytes impair efficacy of antiretroviral therapy","volume":"154","author":"Couturier","year":"2018","journal-title":"Antiviral Res"},{"issue":"1","key":"10.1016\/j.bcp.2023.116010_b0165","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1128\/AAC.00842-09","article-title":"Pharmacokinetics and safety of S\/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers","volume":"54","author":"Min","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2023.116010_b0170","doi-asserted-by":"crossref","unstructured":"M. Shao et al., \u201cDe novo adipocyte differentiation from Pdgfr\u03b2+ preadipocytes protects against pathologic visceral adipose expansion in obesity.,\u201d Nat Commun, vol. 9, no. 1, p. 890, Mar. 2018, doi: 10.1038\/s41467-018-03196-x.","DOI":"10.1038\/s41467-018-03196-x"},{"issue":"3","key":"10.1016\/j.bcp.2023.116010_b0175","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/jac\/dky507","article-title":"Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients","volume":"74","author":"Calza","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bcp.2023.116010_b0180","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-25124-0_10","article-title":"Translational and post-translational control of leptin production by fat cells","author":"Kandror","year":"2016","journal-title":"Post-Transcriptional Mechanisms in Endocrine Regulation"},{"issue":"12","key":"10.1016\/j.bcp.2023.116010_b0185","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.2337\/db07-0510","article-title":"Essential role of mitochondrial function in adiponectin synthesis in adipocytes","volume":"56","author":"Koh","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2023.116010_b0190","doi-asserted-by":"crossref","unstructured":"T. M. Sirey and C. P. Ponting, \u201cInsights into the post-transcriptional regulation of the mitochondrial electron transport chain,\u201d Biochem Soc Trans, vol. 44, no. 5, 2016, doi: 10.1042\/BST20160100.","DOI":"10.1042\/BST20160100"},{"issue":"19","key":"10.1016\/j.bcp.2023.116010_b0195","doi-asserted-by":"crossref","first-page":"Oct","DOI":"10.3390\/cells11193104","article-title":"Prolonged Antiretroviral Treatment Induces Adipose Tissue Remodelling Associated with Mild Inflammation in SIV-Infected Macaques","volume":"11","author":"Mausol\u00e9o","year":"2022","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.bcp.2023.116010_b0200","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1016\/S2352-3018(21)00163-6","article-title":"Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium","volume":"8","author":"Bansi-Matharu","year":"2021","journal-title":"Lancet HIV"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223006032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223006032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:19:27Z","timestamp":1762096767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295223006032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":40,"alternative-id":["S0006295223006032"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2023.116010","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Divergent effects of the antiretroviral drugs, dolutegravir, tenofovir alafenamide, and tenofovir disoproxil fumarate, on human adipocyte function","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2023.116010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116010"}}